- Supported exchanges /
- NASDAQ /
- ATYR.NASDAQ
aTyr Pharma, Inc. (ATYR NASDAQ) stock market data APIs
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma, Inc. Financial Data Overview
| 3.29 | |
| 3.11 | |
| - | |
| 3.3699 | |
| 3.055 | |
| 1.14-3.8 | |
| 144 M | |
| 75 796 K | |
| 588 K | |
| -0.2277 | |
| 1.214 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
aTyr Pharma, Inc. Fundamental Data is available in our Financial Data APIs
- Net Revenue 588 K
- EBITDA -61 819 000
- Earnings Per Share -0.9
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get aTyr Pharma, Inc. Earnings via APIs
- Latest Release 2024-11-07
- EPS/Forecast -0.22
Get aTyr Pharma, Inc. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
